OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Communications is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Kindlin‐1 drives early steps of breast cancer metastasis	563
	380
	347
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor	284
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity	272
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”	254
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort	233
Issue Information	211
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation	207
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma	165
Issue Information	159
Issue Information	158
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma	149
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy	146
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study	144
Dysregulated proline metabolism exacerbates HCC metastasis via EPRS1-mediated mRNA translation	141
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update	133
Current status and perspectives of esophageal cancer: a comprehensive review	131
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives	127
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h	122
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial	113
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer	111
	102
	101
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity	95

EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer	94
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses	94
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica	93
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of	78
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study	69
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence	67
Issue Information	67
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions	65
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases	65
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward	65
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer	64
Issue Information	61
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial	60
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer	60
N ⁶ ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas	60
FOXO1 or not FOXO1: that is the question	59
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma	59
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML	58
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma	57
Cover Image, Volume 45, Issue 6	56
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials	56
Issue Information	54
Ubiquitination in cancer: mechanisms and therapeutic opportunities	53
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism	53
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia	53
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene	51